• About Constellation
  • Mission Statement & Core Values
  • Management
  • Board of Directors
  • Founders, Fellows, & Advisors
  • Investors
• Research & Development
  • Epigenetics Overview
  • Constellation Product Engine
  • Constellation Pipeline
• Newsroom
  • Constellation in the News
• Careers
  • Company Culture
  • Job Opportunities
  • Apply Online

Management

Mark A. Goldsmith, M.D., Ph.D.
President and Chief Executive Officer

Dr. Mark Goldsmith joined Constellation as president and CEO in June 2009. He previously held senior executive positions in the biotechnology industry and academia. Prior to his appointment at Constellation, Dr. Goldsmith was Senior Executive-in-Residence at Prospect Venture Partners, a leading healthcare venture capital firm. Previously he served as CEO of Cogentus Pharmaceuticals and as senior vice president leading the health care division of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was consultant to leading pharmaceutical and biotechnology companies.

James E. Audia, Ph.D.
Chief Scientific Officer

Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.

Michael R. Cooper, M.D. 
 Chief Medical Officer

Dr. Cooper joined Constellation Pharmaceuticals in 2011 as its Chief Medical Officer. Before joining Constellation Dr. Cooper held leadership positions at Novartis Pharmaceuticals, where he was Clinical Head of Oncology Translational Medicine in Cambridge, Massachusetts, and at Millennium Pharmaceuticals, where he was Vice President of Oncology Clinical Development. Before joining the pharmaceutical industry, Dr. Cooper practiced medical oncology and hematology in various academic institutions, where he led programs in the early clinical development of novel anti-cancer compounds. His interest in cancer pharmacology, pharmacokinetics and biomarker development was developed during his tenure as a Senior Clinical Investigator in the Clinical Pharmacology and Medicine Branches of the National Cancer Institute in Bethesda, Maryland. Dr. Cooper received his M.D. from Duke University School of Medicine, which is also where he completed his residency in internal medicine and his fellowship in hematology and medical oncology.

Garen Bohlin

Executive Vice President

Mr. Garen Bohlin became Executive Vice President of Constellation in January 2010 and is responsible for corporate operations and finance functions. For the past 25 years, he has held senior executive posts in leading biotechnology companies. Most recently prior to joining Constellation, Mr. Bohlin served as Chief Operating Officer of Sirtris Pharmaceuticals, where he played key roles in the general management of Sirtris, as well as in its initial public offering, the sale of the company to GlaxoSmithKline for over $700 million, and the post-acquisition integration. Previously, he was the founding CEO of Syntonix Pharmaceuticals, where he positioned the company for its eventual sale to Biogen Idec. Earlier in his career, he held multiple executive positions at Genetics Institute, where he played an integral role in structuring the sale of Genetics Institute to American Home Products (Wyeth) at an implied valuation of approximately $3 billion.

Brenda J. Sousa
Vice President of Human Resources

Ms. Brenda Sousa joined Constellation as Vice President of Human Resources for Constellation in March 2010.  Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices.  Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare.  Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing.  Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board.  Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.